Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7560)
All Articles published online
|
Publishing Process of This Article
|
Jun 28, 2015 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, Tisone G, Simonetti G. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol 2015; 7(12): 1694-1700 [PMID: 26140089 DOI: 10.4254/wjh.v7.i12.1694] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i12/1694.htm |
| Number | Citing Articles |
| 1 |
Hai-Tao Zhao, Jian-Qiang Cai. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World Journal of Gastroenterology 2021; 27(47): 8069-8080 doi: 10.3748/wjg.v27.i47.8069
|
| 2 |
Christof M Sommer, Thuy D Do, Christopher L Schlett, Paul Flechsig, Theresa L Gockner, Anja Kuthning, Dominik F Vollherbst, Philippe L Pereira, Hans U Kauczor, Stephan Macher-Göppinger. In vivo characterization of a new type of biodegradable starch microsphere for transarterial embolization. Journal of Biomaterials Applications 2018; 32(7): 932 doi: 10.1177/0885328217746674
|
| 3 |
Roberto Mazzanti, Umberto Arena, Renato Tassi. Hepatocellular carcinoma: Where are we?. World Journal of Experimental Medicine 2016; 6(1): 21-36 doi: 10.5493/wjem.v6.i1.21
|
| 4 |
Thierry de Baere, Lambros Tselikas, Frederic Deschamps, Valerie Boige, Michel Ducreux, Antoine Hollebecque. Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. Hepatic Oncology 2016; 3(2): 109 doi: 10.2217/hep-2015-0001
|
| 5 |
Yanmei Dai, Huijie Jiang, Shi-Ting Feng, Yuwei Xia, Jinping Li, Sheng Zhao, Dandan Wang, Xu Zeng, Yusi Chen, Yanjie Xin, Dongmin Liu. Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2022; : 273 doi: 10.2147/JHC.S351077
|
| 6 |
Pierleone Lucatelli, Gianluca De Rubeis, Fabrizio Basilico, Luca Ginanni Corradini, Mario Corona, Mario Bezzi, Carlo Catalano. Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. La radiologia medica 2019; 124(12): 1212 doi: 10.1007/s11547-019-01076-y
|
| 7 |
Kohei Ogawa, Yasutsugu Takada. Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation. Cancers 2022; 14(2): 396 doi: 10.3390/cancers14020396
|
| 8 |
Aysheh Alrfooh, Aditi Patel, Sandeep Laroia. Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers. Nuclear Medicine and Molecular Imaging 2021; 55(4): 162 doi: 10.1007/s13139-021-00709-3
|
| 9 |
Haoyang Bei, Weiheng Mai, Weifeng Chen, Mingyi Li, Yongguang Yang. Application of systemic treatment in conversion therapy options for liver cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.966821
|
| 10 |
Georg Györi, Pierre-Alain Clavien, Mickaël Lesurtel. Hepatocellular Carcinoma. 2016; : 477 doi: 10.1007/978-3-319-34214-6_32
|
| 11 |
Shuguang Ju, Chen Zhou, Junwen Hu, Yingliang Wang, Chaoyang Wang, Jiacheng Liu, Chongtu Yang, Songjiang Huang, Tongqiang Li, Yang Chen, Yaowei Bai, Wei Yao, Bin Xiong. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09451-1
|
| 12 |
Roberto Minici, Maria Anna Siciliano, Michele Ammendola, Rita Carlotta Santoro, Vito Barbieri, Girolamo Ranieri, Domenico Laganà. Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers 2022; 15(1): 257 doi: 10.3390/cancers15010257
|
| 13 |
Isabelle Mohr, Marie Vogeler, Jan Pfeiffenberger, Simon David Sprengel, Miriam Klauss, Boris Radeleff, Andreas Teufel, De-Hua Chang, Christoph Springfeld, Thomas Longerich, Uta Merle, Arianeb Mehrabi, Karl Heinz Weiss, Markus Mieth. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2022; 148(11): 3163 doi: 10.1007/s00432-021-03900-3
|
| 14 |
Qin Shi, Jiacheng Liu, Tongqiang Li, Chen Zhou, Yingliang Wang, Songjiang Huang, Chongtu Yang, Yang Chen, Bin Xiong. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis. Clinics and Research in Hepatology and Gastroenterology 2022; 46(5): 101893 doi: 10.1016/j.clinre.2022.101893
|
| 15 |
Johannes Haubold, Markus P. Reinboldt, Axel Wetter, Yan Li, Johannes Maximilian Ludwig, Christian Lange, Heiner Wedemeyer, Clemens Schotten, Lale Umutlu, Jens Theysohn. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2020; 192(09): 862 doi: 10.1055/a-1111-9955
|
| 16 |
Lei Xu, Lin Chen, Wei Zhang. Neoadjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery 2021; 13(12): 1550-1566 doi: 10.4240/wjgs.v13.i12.1550
|
| 17 |
Roberto Minici, Michele Ammendola, Francesco Manti, Maria Anna Siciliano, Marco Minici, Iman Komaei, Giuseppe Currò, Domenico Laganà. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.634087
|
| 18 |
Johannes M. Ludwig, Roberto Iezzi, Jens M. Theysohn, Thomas Albrecht, Alessandro Posa, Alexander Gross. European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden. Cancers 2021; 13(20): 5122 doi: 10.3390/cancers13205122
|